228 related articles for article (PubMed ID: 11209448)
1. Indirect cost of ischemic heart disease to employers.
Guico-Pabia CJ; Murray JF; Teutsch SM; Wertheimer AI; Berger ML
Am J Manag Care; 2001 Jan; 7(1):27-34. PubMed ID: 11209448
[TBL] [Abstract][Full Text] [Related]
2. The economic consequences of irritable bowel syndrome: a US employer perspective.
Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
[TBL] [Abstract][Full Text] [Related]
3. Economic cost of Guillain-Barré syndrome in the United States.
Frenzen PD
Neurology; 2008 Jul; 71(1):21-7. PubMed ID: 18591502
[TBL] [Abstract][Full Text] [Related]
4. Indirect cost of ischemic heart disease to employers.
Sherman B
Am J Manag Care; 2001 Apr; 7(4):330-1. PubMed ID: 11310189
[No Abstract] [Full Text] [Related]
5. Costs of illness: United States, 1980.
Parsons PE; Lichtenstein R; Berki SE; Murt HA; Lepkowski JM; Stehouwer SA; Landis JR
Natl Med Care Util Expend Surv C; 1986 Apr; (3):1-90. PubMed ID: 10313412
[TBL] [Abstract][Full Text] [Related]
6. Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association
Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
[TBL] [Abstract][Full Text] [Related]
7. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States.
Brook RA; Wahlqvist P; Kleinman NL; Wallander MA; Campbell SM; Smeeding JE
Aliment Pharmacol Ther; 2007 Sep; 26(6):889-98. PubMed ID: 17767473
[TBL] [Abstract][Full Text] [Related]
8. Total costs of IBS: employer and managed care perspective.
Cash B; Sullivan S; Barghout V
Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
Sasser AC; Rousculp MD; Birnbaum HG; Oster EF; Lufkin E; Mallet D
Womens Health Issues; 2005; 15(3):97-108. PubMed ID: 15894195
[TBL] [Abstract][Full Text] [Related]
10. Economic cost and epidemiological characteristics of patients with fibromyalgia claims.
Robinson RL; Birnbaum HG; Morley MA; Sisitsky T; Greenberg PE; Claxton AJ
J Rheumatol; 2003 Jun; 30(6):1318-25. PubMed ID: 12784409
[TBL] [Abstract][Full Text] [Related]
11. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.
Joish VN; Donaldson G; Stockdale W; Oderda GM; Crawley J; Sasane R; Joshua-Gotlib S; Brixner DI
Curr Med Res Opin; 2005 Apr; 21(4):535-44. PubMed ID: 15899102
[TBL] [Abstract][Full Text] [Related]
12. The costs of cancer to a major employer in the United States: a case-control analysis.
Barnett A; Birnbaum H; Cremieux PY; Fendrick AM; Slavin M
Am J Manag Care; 2000 Nov; 6(11):1243-51. PubMed ID: 11185849
[TBL] [Abstract][Full Text] [Related]
13. Tegaserod treatment for IBS: a model of indirect costs.
Smith DG; Barghout V; Kahler KH
Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
[TBL] [Abstract][Full Text] [Related]
14. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective.
Vicente-Herrero T; Burke TA; Laínez MJ
Curr Med Res Opin; 2004 Nov; 20(11):1805-14. PubMed ID: 15537481
[TBL] [Abstract][Full Text] [Related]
15. The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective.
Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
Manag Care Interface; 2007 Oct; 20(10):26-32. PubMed ID: 18405204
[TBL] [Abstract][Full Text] [Related]
16. The annual impact of seasonal influenza in the US: measuring disease burden and costs.
Molinari NA; Ortega-Sanchez IR; Messonnier ML; Thompson WW; Wortley PM; Weintraub E; Bridges CB
Vaccine; 2007 Jun; 25(27):5086-96. PubMed ID: 17544181
[TBL] [Abstract][Full Text] [Related]
17. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
Li-McLeod J; Perfetto EM
Manag Care Interface; 2001 Feb; 14(2):52-9. PubMed ID: 11228817
[TBL] [Abstract][Full Text] [Related]
18. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
Lo Sasso AT; Rost K; Beck A
Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
[TBL] [Abstract][Full Text] [Related]
19. [Smoking-attributable productivity loss in Germany--a partial sickness cost study based on the human capital potential method].
Wegner C; Gutsch A; Hessel F; Wasem J
Gesundheitswesen; 2004 Jul; 66(7):423-32. PubMed ID: 15314734
[TBL] [Abstract][Full Text] [Related]
20. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data.
Merkesdal S; Ruof J; Huelsemann JL; Mittendorf T; Handelmann S; Mau W; Zeidler H
Arthritis Rheum; 2005 Apr; 53(2):234-40. PubMed ID: 15818718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
